Clinical trials: Drug Eluting Stents
Arterial Occlusive Diseases, Myocardial Ischemia
RESOLUTE Japan - The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent
The objective of the study is to verify the safety and efficacy of the MDT-4107 Drug-Eluting Coronary Stent for the treatment of de novo lesions in native coronary arteries.
- Conditions
- Arterial Occlusive Diseases, Myocardial Ischemia, Cardiovascular Diseases, Coronary Artery Disease
- Trial name
- RJ (NCT00927940)
- Testing
- MDT-4107 Drug Eluting Stent
- Where
- 14 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Medtronic Vascular
Coronary Heart Disease, Drug Eluting Stent
Study on Absorbable Zinc Alloy Drug Eluting Coronary Stent System
This trial is a prospective, two center single group registration pilot trial aiming to evaluate the product safety, and provide information for the later confirmatory test design according to the results.
- Trial name
- NCT05477940
- Testing
- Absorbable zinc alloy drug eluting coronary stent system
- Volunteers
- 30 people
- Sponsor
- Shandong Branden Med.Device Co.,Ltd
Coronary Artery Disease
The Direct III Post Market Study
The primary objective of this multicenter, single-arm, observational study is to evaluate the feasibility of a systematic direct stenting strategy with the Svelte SLENDER IDS Sirolimus-Eluting Coronary Stent-on-a-Wire Integrated…
- Trial name
- Direct III (NCT02693158)
- Where
- 8 sites in Netherlands
- Volunteers
- 440 people
- Sponsor
- Svelte Medical Systems, Inc.
Angioplasty, Chronic Coronary Occlusion
XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study
This is a prospective, observational, single-arm, open-label, multicenter, postapproval registry study in China. The purpose of this study is to: Evaluate the continued safety and effectiveness of the XIENCE V EECSS in a cohort…
- Conditions
- Angioplasty, Chronic Coronary Occlusion, Stent Thrombosis, Vascular Disease
- Trial name
- XV CHINA SAS (NCT01249027)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
- Where
- United States
- Volunteers
- 2,605 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Randomized, Two-arm, Non-inferiority Study Comparing Endeavor-Resolute Stent With Abbot Xience-V Stent
The RESOLUTE-III Allcomers trial is a prospective, multicenter, randomized, two-arm, international, non-inferiority, open-label study with 2300 patients at 15-20 centers. The study is a "real world, all comers" study.
- Trial name
- RESOLUTE-AC (NCT00617084)
- Testing
- Medtronic Endeavor Resolute, Abbott Xience V
- Where
- Switzerland
- Volunteers
- 2,292 people
- Sponsor
- Medtronic Vascular
Coronary Disease
Multi-Center Clinical Trial: Evaluation of Effectiveness and Safety
This trial aims to demonstrate the non-inferiority of the CI-CMS-005 Coronary Stent System to the study device as well as to the TAXUS™ Express2™ Drug-Eluting Coronary Stent System in in-segment late lumen loss at 9 months after…
- Trial name
- NCT00415961
- Testing
- CoStar Paclitaxel Drug-Eluting Coronary Stent System
- Where
- Japan
- Volunteers
- 120 people
- Sponsor
- Conor Medsystems
Coronary Artery Diseases
BIOFLOW-III UK Satellite Registry Orsiro Stent System
Clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES). 500 subjects will be enrolled in this registry.
- Trial name
- NCT02257710
- Testing
- Orsiro
- Where
- 4 sites in United Kingdom
- Volunteers
- 500 people
- Sponsor
- Biotronik UK Ltd.
Antiplatelet Aggregation
A Study to Evaluate the Discontinuation Effect of Clopidogrel After Drug Eluting Stent Implantation in Non-diabetic Patients
The purpose of the study is to look at the biomarkers of inflammation and platelet activation in patients with drug eluting stents implanted approximately 12 months ago on aspirin and statin, for a 4-week period after the routine…
- Trial name
- DECADES (NCT00493779)
- Testing
- Blood Collection
- Where
- 6 sites in France, Germany and 2 more
- Volunteers
- 103 people
- Sponsor
- Bristol-Myers Squibb
Coronary Artery Disease
V-Flex Plus PTX Drug Eluting Coronary Stent
The study is intended to collect data to evaluate effectiveness and safety of drug eluting stent devices in a dose ranging assessment.
- Trial name
- ELUTES III (NCT00225693)
- Testing
- drug eluting coronary stent
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Cook Group Incorporated
Coronary Artery Disease, Antineoplastic Agents
Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System Clinical Study
The Bioheart Randomized Controlled Trial is a prospective multicentred paralleled study, which will enroll 430 patients and randomized 1:1 to study group and control group.
- Trial name
- NCT03284255
- Testing
- study group, control group
- Where
- 25 sites in China
- Volunteers
- 431 people
- Sponsor
- Shanghai Bio-heart Biological Technology Co., Ltd.
Atherosclerotic Coronary Artery Disease
An Observational Safety Evaluation of Patients Treated With the NEVO™ Sirolimus-eluting Coronary Stent. (NEVO II)
As a result of the implementation of Protocol Am3.0, the design and objective of the NEVO II trial were changed to focus on the safety follow-up of the 103 NEVO™ subjects.
- Trial name
- NEVO II (NCT01202058)
- Testing
- NEVO™ Sirolimus-eluting Coronary Stent System, XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System)
- Where
- 3 sites in Netherlands, Spain and 1 more
- Volunteers
- 156 people
- Sponsor
- Cordis US Corp.
Multi Vessel Coronary Artery Disease, Percutaneous Coronary Intervention
Clinical Impact of DCB-based Versus DES-based Intervention in Patients With MVCAD
This study aimes to compare the clinical outcomes of drug-coated balloon-based percutaneous coronary intervention (DCB-based PCI) and drug-eluting stent-based percutaneous coronary intervention (DES-based PCI) in patients with…
- Trial name
- DCBMultivessel (NCT07539324)
- Testing
- GENOSS® DCB (Paclitaxel-coated PTCA balloon catheter), Contemporary Drug-Eluting Stents (DES)
- Where
- South Korea
- Volunteers
- 892 people
- Sponsor
- Genoss Co., Ltd.
Coronary Artery Disease, Atherosclerosis, Coronary
Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
The objective of this study is to assess the safety and efficacy of the Orsiro Sirolimus Eluting Coronary Stent System in the treatment of subjects with up to three native de novo or restenotic (standard PTCA only) coronary…
- Conditions
- Coronary Artery Disease, Atherosclerosis, Coronary, Myocardial Ischemia, Ischemic Heart Disease
- Trial name
- BIOFLOW-V (NCT02389946)
- Testing
- Orsiro DES, Xience DES
- Where
- 92 sites in United States, Australia and 11 more
- Volunteers
- 1,334 people
- Sponsor
- Biotronik, Inc.
Coronary Artery Disease
The ENDEAVOR IV Clinical Trial: A Trial of a Coronary Stent System in Coronary Artery Lesions
The purpose of this study is to assess the equivalence in safety and efficacy of the Endeavor Drug Eluting Coronary Stent System when compared to the Taxus Paclitaxel-Eluting Coronary Stent System for the treatment of single de…
- Trial name
- ENDEAVOR IV (NCT00217269)
- Testing
- Coronary Artery Stenting
- Where
- United States
- Volunteers
- 1,548 people
- Sponsor
- Medtronic Vascular
Coronary Artery Disease, Ischemic Heart Disease
Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial
This trial will evaluate Orbital Atherectomy compared to conventional balloon angioplasty technique for the treatment of severely calcified lesions prior to implantation of drug-eluting stents (DES).
- Conditions
- Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction
- Trial name
- ECLIPSE (NCT03108456)
- Testing
- Orbital Atherectomy, Balloon
- Where
- 104 sites in United States
- Volunteers
- 2,005 people
- Sponsor
- Abbott Medical Devices
Emphysema
Exhale (R) Stent for Emphysema
Current treatment for emphysema is limited to measures that include inhaled oxygen, bronchodilators, anti-inflammatory drugs and pulmonary rehabilitation.
- Trial name
- NCT00207337
- Testing
- Exhale Drug-Eluting Stent
- Where
- 6 sites in Australia, Brazil and 1 more
- Volunteers
- 60 people
- Sponsor
- Broncus Technologies
Coronary Disease, Coronary Artery Disease
SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in Europe
The purpose of this Clinical Evaluation is a continuation in the assessment of the performance of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the treatment of patients with de novo coronary artery…
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- SPIRIT V (NCT00402272)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent
- Where
- 93 sites in Austria, Belgium and 21 more
- Volunteers
- 2,700 people
- Sponsor
- Abbott Medical Devices
Diabetes Mellitus
BLADE-PCI Trial (BLADE); PHASE IIB LIPOSOMAL ALENDRONATE STUDY
The main objective of this study is to assess the safety, efficacy and dose response of LABR-312 administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent in reducing restenosis…
- Trial name
- BLADE (NCT02645799)
- Testing
- LABR-312
- Where
- Israel
- Volunteers
- 270 people
- Sponsor
- BIOrest Ltd.
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Belgium Satellite Registry
This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Trial name
- NCT01831336
- Where
- 8 sites in Belgium
- Volunteers
- 332 people
- Sponsor
- Biotronik Belgium NV
Coronary Disease
A Randomized, Multi-Center Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent Systems (GENESIS)
To demonstrate non-inferiority in 6-month angiographic in-stent late lumen loss of the pimecrolimus-eluting coronary stent (Corio) compared to the CoStar coronary stent control arm and the dual pimecrolimus/paclitaxel-eluting…
- Trial name
- NCT00322569
- Testing
- Corio™ Pimecrolimus-Eluting Coronary Stent System, SymBio™ Pimecrolimus/Paclitaxel-Eluting Coronary Stent System, Costar ™ Paclitaxel-Eluting Coronary Stent System
- Where
- United Kingdom
- Volunteers
- 246 people
- Sponsor
- Cordis US Corp.